The Reflux Company, a healthcare technology company focused exclusively on the diagnosis and treatment of reflux-related diseases, has raised $1 million in an oversubscribed seed funding round to accelerate commercial expansion, strengthen its product portfolio, and support global market growth. The round included participation from MAAB Group, which invested as part of a strategic partnership focused on commercial development, distribution, and market access in Asia, particularly China.

Founded in 2025 by Thomas Ball, Ph.D., The Reflux Company is building a unified platform that brings together diagnostic tools, therapeutic devices, software, and patient-focused services for people affected by Laryngopharyngeal Reflux (LPR) and Gastroesophageal Reflux Disease (GERD). The company aims to provide a more comprehensive approach to reflux care by connecting technologies used for diagnosis and treatment within a single healthcare ecosystem.

The newly secured funding will support The Reflux Company’s efforts to expand its commercial footprint, develop partnerships, and advance adoption of its reflux-focused healthcare solutions. The company plans to use the capital to accelerate growth in existing markets, expand internationally, and continue building its platform around technologies designed to improve reflux diagnosis and management.

Reflux disease affects millions of patients worldwide, yet diagnosis and treatment can often be complex. Many patients experience symptoms that may not immediately be connected to reflux, including chronic cough, throat irritation, hoarseness, and other upper airway issues. The Reflux Company was created to address these challenges by combining multiple diagnostic and therapeutic solutions into a coordinated platform designed for both clinicians and patients.

The company’s portfolio includes several reflux-related technologies, including Restech Dx-pH, a diagnostic system designed to detect changes in pH in the upper airway; Stretta, a minimally invasive procedure for certain patients with chronic GERD; Reflux Band, an external device designed to reduce nighttime reflux reaching the throat; and PepsinCheck, a saliva-based reflux test.

The investment from MAAB Group represents both financial backing and a strategic commercial collaboration. MAAB Group has been appointed as The Reflux Company’s advisory service partner for Asia, with a focus on China. The partnership includes support for market access, distribution, business development, commercialization, and additional fundraising activities.

MAAB Group is a healthcare-focused investment and commercialization platform founded by pharmaceutical industry veterans. The company specializes in cross-border licensing, market expansion, and commercialization of innovative healthcare technologies. Its investment in The Reflux Company marks a strategic effort to support the company’s expansion into Asian healthcare markets.

The funding round comes as healthcare companies increasingly focus on specialized platforms that address specific disease areas. Rather than developing a single product, The Reflux Company is building an integrated ecosystem designed to support the entire patient journey, from identifying reflux conditions to providing treatment options and ongoing management.

The company’s approach is based on combining established medical technologies with a broader commercial and patient-care strategy. The Reflux Company has assembled a portfolio of products that includes existing technologies with clinical use and is working to expand access through partnerships with healthcare providers and distributors.

Thomas Ball, Ph.D., founder and CEO of The Reflux Company, has positioned the company around the need for better solutions for reflux patients and clinicians. Under his leadership, the company has focused on creating a global platform dedicated specifically to reflux-related conditions, bringing together diagnostics and treatments that address different stages of care.

The company’s expansion strategy includes strengthening its presence in existing markets while pursuing opportunities internationally. The partnership with MAAB Group is expected to help The Reflux Company navigate regulatory, commercial, and distribution opportunities in Asia, one of the world’s largest healthcare markets.

With the seed financing secured, The Reflux Company plans to continue developing its platform, expanding access to its technologies, and building partnerships with healthcare organizations around the world. The company’s long-term goal is to establish a global reflux care ecosystem that improves diagnosis, treatment, and patient outcomes for people affected by GERD and LPR.

Related Articles